Mouse anti-Human Cancer Antigen CA15-3 Monoclonal Antibody

Monoclonal Anti-Cancer Antigen CA15-3 (Capture Ab)

Cat. Num. AAA355910

• Reactivity: Human
• Applications: ELISA, Immunohistochemistry, Western Blot
• Purity: Protein A or G purified and supplied in 150 mM NaCl & 10 mM Tris, pH7.4 with 0.05% NaN3. Purity: >90% by SDS-PAGE
• Synonyms: Cancer Antigen CA15-3; Monoclonal Antibody; Monoclonal Anti-Cancer Antigen CA15-3 (Capture Ab); anti-Cancer Antigen CA15-3 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG1
• Clone Number: P3
• Specificity: It recognizes a sialylated carbohydrate epitope of the MUC-1 glycoprotein. It is sensitive to periodate and sialidase treatment, but it does not react with glycolipid extract from the ZR75-1 cell line.
• Purity/Purification: Protein A or G purified and supplied in 150 mM NaCl & 10 mM Tris, pH7.4 with 0.05% NaN3. Purity: >90% by SDS-PAGE
• Form/Format: Liquid
• Concentration: 11 mg/ml (varies by lot)

• Applicable Applications for anti-Cancer Antigen CA15-3 antibody: ELISA (EIA), CLIA, Immunohistochemistry (IHC), Western Blot (WB)
• Immunogen: Immunogen MUC-1 / CA15-3 protein secreted from human breast cancer cell line ZR75-1.
• Preparation and Storage: Aliquot and store at -20 degree C for long term (at least for one year).

Related Product Information for anti-Cancer Antigen CA15-3 antibody

CA 15-3, for Carcinoma Antigen 15-3, is a tumor marker for many types of cancer, most notably breast cancer. It is derived from MUC1. CA 15-3 and associated CA 27-29 are different epitopes on the same protein antigen product of the breast cancer-associated MUC1 gene. Elevated CA15-3, in conjunction with alkaline phosphatase (ALP), was found to be associated with an increased chance of early recurrence in breast cancer. Both CA 15-3 and CA 27-29 may be elevated in patients with benign ovarian cysts, benign breast disease, and benign liver disease. Elevations may also be seen in cirrhosis, sarcoidosis and lupus.

References

1. Duffy MJ, Duggan C, Keane R, et al. (March 2004). "High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer". Clin. Chem. 50 (3): 559–63.
2. Bearz A, Talamini R, Vaccher E, et al. (2007). "MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients". Int. J. Biol. Markers. 22 (4): 307–11.